Lipitor vs Crestor Side Effects: Atorvastatin vs Rosuvastatin Head-to-Head

How the Two Statins Compare Pharmacologically

Atorvastatin and rosuvastatin both inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Their side-effect differences stem primarily from pharmacokinetic properties, not pharmacodynamic ones. Rosuvastatin is hydrophilic; atorvastatin is lipophilic.

This lipophilicity distinction matters clinically. Lipophilic statins cross cell membranes more readily, which may explain differential muscle penetration. A 2015 meta-analysis of 135 randomized trials (N=246,955) published in the European Heart Journal found no statistically significant difference in overall discontinuation rates between the two drugs 1. Atorvastatin is metabolized through CYP3A4, creating interaction potential with macrolide antibiotics, azole antifungals, protease inhibitors, and grapefruit juice. Rosuvastatin undergoes minimal CYP2C9 metabolism and is largely excreted unchanged, reducing its drug-interaction burden substantially.

Rosuvastatin is approximately 1.5 to 2 times more potent per milligram. A 10 mg dose of rosuvastatin produces LDL reductions comparable to 20-40 mg of atorvastatin. This potency difference means clinicians can often use lower absolute doses of rosuvastatin, which may reduce dose-dependent adverse events. The STELLAR trial (2003, N=2,431) confirmed that rosuvastatin 10 mg reduced LDL-C by 46% compared to 37% with atorvastatin 10 mg 2.

Muscle-Related Side Effects

Myalgia is the most common reason patients stop taking statins. Both atorvastatin and rosuvastatin produce muscle complaints in 5-10% of trial participants, though observational studies report rates up to 20-29% when patient self-reporting is included.

The 2012 STOMP trial (N=420) specifically assessed statin effects on muscle. Atorvastatin 80 mg increased creatine kinase (CK) levels by a mean of 20.8 IU/L compared to placebo, without a significant increase in myalgia rates meeting the primary endpoint 3. Rhabdomyolysis, the most feared muscular complication, occurs in fewer than 1 in 10,000 patients per year with either drug. The FDA Adverse Event Reporting System shows no meaningful difference in rhabdomyolysis signal between the two molecules when adjusted for prescription volume.

A practical distinction: atorvastatin's CYP3A4 dependence means co-administration with inhibitors of that enzyme (clarithromycin, itraconazole, ritonavir) can raise atorvastatin plasma levels 2- to 4-fold, amplifying muscle toxicity risk. Rosuvastatin avoids this particular hazard. For patients on complex medication regimens, particularly those with HIV on protease inhibitors or transplant recipients on cyclosporine, this interaction profile often tips the prescribing decision toward rosuvastatin at adjusted doses.

"The choice between atorvastatin and rosuvastatin for muscle-sensitive patients often comes down to concomitant medications rather than intrinsic myotoxicity," states the 2018 ACC/AHA Cholesterol Clinical Practice Guideline 4.

Diabetes Risk

Both statins increase the risk of new-onset type 2 diabetes. This is a class effect. The magnitude differs slightly between the two drugs at higher doses.

In the JUPITER trial (N=17,802), rosuvastatin 20 mg daily was associated with a 25% relative increase in physician-reported diabetes compared to placebo (3.0% vs 2.4% over a median 1.9 years of follow-up) 5. A 2010 meta-analysis in The Lancet (N=91,140 across 13 statin trials) found that statin therapy as a class produced a 9% increased odds of incident diabetes (OR 1.09, 95% CI 1.02-1.17) 6. A subsequent individual-patient-data meta-analysis suggested that higher-potency regimens (including rosuvastatin 20 mg and atorvastatin 80 mg) carried the greatest diabetes hazard.

The clinical calculus remains favorable. For every 1,000 patients treated with high-intensity statins for 5 years, approximately 5 additional diabetes cases occur, while 50-100 cardiovascular events are prevented. The ACC/AHA guidelines explicitly state that diabetes risk should not deter statin initiation in patients meeting treatment thresholds.

Risk factors that amplify statin-associated diabetes include metabolic syndrome, impaired fasting glucose, BMI >30, and HbA1c 5.7-6.4%. In these patients, either statin carries similar excess risk. No head-to-head trial has demonstrated a statistically significant difference in diabetes incidence between atorvastatin and rosuvastatin at equipotent doses.

Liver Effects and Hepatotoxicity

Clinically significant hepatotoxicity (defined as ALT elevation >3 times the upper limit of normal) occurs in under 1% of patients on either drug. The FDA removed the requirement for routine liver function monitoring during statin therapy in 2012, based on decades of safety data showing that serious liver injury is idiosyncratic, not dose-dependent in a predictable pattern.

In ASCOT-LLA (N=10,305), atorvastatin 10 mg produced ALT elevations >3x ULN in 0.8% of patients versus 0.5% on placebo over 3.3 years of median follow-up 7. The JUPITER trial reported hepatic transaminase elevations in 0.3% of the rosuvastatin group. A 2017 systematic review in Hepatology confirmed that statin hepatotoxicity requiring discontinuation occurs at a rate of approximately 1 per 100,000 patient-years for both drugs, and that statins are now considered safe even in patients with nonalcoholic fatty liver disease 8.

Atorvastatin has one relevant hepatic distinction: because CYP3A4 metabolizes it in the liver, patients with hepatic impairment may have increased drug exposure. Rosuvastatin's renal elimination pathway means severe hepatic impairment (Child-Pugh C) is a contraindication for rosuvastatin at doses above 10 mg, per its prescribing information, but for different reasons related to altered protein binding rather than accumulation of active metabolites.

Renal Effects and Proteinuria

Rosuvastatin produces dose-dependent proteinuria at a higher rate than atorvastatin. This effect is tubular in origin, not glomerular, and is generally reversible upon dose reduction. At 40 mg (the maximum approved dose), rosuvastatin-associated proteinuria was observed in approximately 3.1% of patients in premarketing trials compared to 1.2% at lower doses.

The mechanism involves inhibition of proximal tubular reabsorption of filtered proteins, not kidney damage. Long-term follow-up studies have not demonstrated progression to renal impairment. The PLANET I trial (N=325) in patients with proteinuric kidney disease found that rosuvastatin 40 mg did not reduce proteinuria and was associated with a non-significant decline in eGFR, while atorvastatin 80 mg produced no such signal 9.

"For patients with pre-existing proteinuria or CKD stage 3-4, atorvastatin may be preferred because its hepatic clearance avoids renal accumulation concerns," notes the Kidney Disease: Improving Global Outcomes (KDIGO) 2013 lipid guideline 10.

In practice, rosuvastatin at 5-20 mg produces proteinuria at rates indistinguishable from atorvastatin. The clinical significance of this finding is debated. The 40 mg dose carries the relevant signal, and most patients achieve target LDL at 10-20 mg.

Cognitive and Neurological Complaints

The FDA added a label warning about cognitive effects (memory loss, confusion) to all statins in 2012. Neither atorvastatin nor rosuvastatin has demonstrated greater cognitive risk in controlled trials.

The HOPE-3 trial (N=12,705) assessed rosuvastatin 10 mg over 5.6 years and found no difference in cognitive decline between statin and placebo groups 11. A dedicated substudy of the PROSPER trial, which used pravastatin rather than the two drugs compared here, similarly found no accelerated cognitive decline. Post-marketing reports exist for both atorvastatin and rosuvastatin, but confounding by age, polypharmacy, and nocebo effects makes causality difficult to establish.

The lipophilicity hypothesis (that lipophilic statins cross the blood-brain barrier more readily, producing more CNS effects) has not been confirmed in human outcome trials. Atorvastatin's greater lipophilicity does not translate into measurably worse cognitive outcomes compared to rosuvastatin.

Gastrointestinal Tolerability

GI symptoms (nausea, diarrhea, constipation, abdominal pain, dyspepsia) occur in 2-5% of patients on either drug. Prescribing information for atorvastatin lists constipation (2.1%), diarrhea (2.7%), and dyspepsia (1.7%) based on pooled clinical trial data. Rosuvastatin's label reports nausea (3.4%), constipation (2.1%), and abdominal pain (2.0%).

These rates are derived from different trial populations and are not directly comparable. No head-to-head study has identified a clinically meaningful GI tolerability difference between the two agents. In practice, switching from one to the other for GI intolerance occasionally helps individual patients, likely due to differences in excipients, timing of dosing relative to meals, or placebo/nocebo dynamics rather than true pharmacological differences in gut toxicity.

Drug Interactions: The Critical Differentiator

Drug interactions represent the largest practical safety difference between these two statins. Atorvastatin's CYP3A4 metabolism creates clinically significant interactions with:

• Strong CYP3A4 inhibitors: clarithromycin, itraconazole, ketoconazole, HIV protease inhibitors, nefazodone
• Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamil, fluconazole
• Grapefruit juice (in quantities >1.2 L/day at standard concentrations)

Rosuvastatin avoids most of these. Its primary interaction concern is with cyclosporine (which increases rosuvastatin AUC 7-fold), gemfibrozil (which doubles exposure), and certain antiretrovirals (lopinavir/ritonavir increases rosuvastatin 2-fold via OATP1B1 inhibition) 12.

The FDA prescribing label for rosuvastatin limits the dose to 5 mg when co-administered with cyclosporine and to 10 mg with gemfibrozil. Atorvastatin's label similarly recommends dose limits with strong CYP3A4 inhibitors but the list of interacting drugs is substantially longer.

For polypharmacy patients on calcium channel blockers (diltiazem, verapamil), macrolide antibiotics, or azole antifungals, rosuvastatin offers a cleaner interaction profile. This advantage is one of the most frequent reasons clinicians switch patients from atorvastatin to rosuvastatin in clinical practice.

Who Should Choose Which Statin

Neither drug is categorically safer than the other. Selection depends on the individual patient's comorbidities, concomitant medications, and dose requirements.

Situations favoring atorvastatin: patients with CKD stages 3b-5 (hepatic clearance avoids renal accumulation), patients already on it with good tolerability, and those needing a statin with strong acute coronary syndrome trial data (PROVE IT-TIMI 22, TNT, SPARCL). Situations favoring rosuvastatin: patients on multiple CYP3A4 substrates, those requiring maximal LDL reduction at the lowest milligram dose, and patients who developed myalgia on atorvastatin where the interaction profile contributed.

The AHA/ACC guidelines do not preferentially recommend one over the other. Both are classified as high-intensity statins at their maximum doses (atorvastatin 40-80 mg, rosuvastatin 20-40 mg). Therapeutic equivalence in cardiovascular outcomes is assumed from indirect trial comparisons: ASCOT-LLA demonstrated a 36% reduction in CHD events with atorvastatin 10 mg in hypertensive patients [7], while JUPITER showed a 44% reduction in major cardiovascular events with rosuvastatin 20 mg in patients with elevated hsCRP [5]. These populations differ enough that direct efficacy comparisons between the trials are not valid.

The most reliable predictor of statin tolerability is prior statin history. Patients who tolerated one statin at moderate intensity will almost always tolerate the equipotent dose of the other.